SCHEMBL981801

SCHEMBL981801

Cc1oc(=O)oc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.40
BRD4 O60885 2/20 0.39
BRD2 P25440 1/20 0.39
KDM4E B2RXH2 5/20 0.39
CYP3A4 P08684 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PDGFRA P16234 1/20 0.39
MAPK8 P45983 1/20 0.39
CDK5 Q00535 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PTGS2 P35354 3/20 0.38
PTGS1 P23219 1/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48083 0.84 KDM4E (0.44) ABCG2KDM4ECYP3A4ALDH1A1MAPT
SCHEMBL305332 0.74 KDM4E (0.38) ABCG2KDM4ECYP3A4MAPTCYP2C9
SCHEMBL10179796 0.74 CTRC (0.38) ABCG2KDM4ECYP3A4MAPTPTGS1
SCHEMBL2468591 0.74 ABCG2 (0.40) ABCG2KDM4ECYP3A4ALDH1A1MAPT
SCHEMBL7128881 0.74 PTGS1 (0.43) ABCG2KDM4ECYP3A4ALDH1A1MAPT
SCHEMBL15161586 0.70 ABCG2 (0.41) ABCG2KDM4ECYP3A4ALDH1A1MAPT
SCHEMBL5492196 0.69 ADORA3 (0.39) ABCG2KDM4ECYP3A4ALDH1A1MAPT
SCHEMBL22356152 0.69 KDM4E (0.44) KDM4ECYP3A4ALDH1A1MAPTCYP2C9
SCHEMBL2719464 0.69 TDO2 (0.42) KDM4ECYP3A4MAPTPTGS2PTGS1
SCHEMBL2721048 0.69 KDM4E (0.35) ABCG2KDM4ECYP3A4ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963428-B1 Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2018-05-08 US claimed
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US claimed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US claimed
EP-2447264-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-05-02 EP claimed
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 US claimed
US-6664008-B1 Comprising solute, cyclic carbonate solvent, and separator; lithium batteries MITSUBISHI CHEMICAL CORPORATION (JP) 2003-12-16 US claimed
WO-2023098426-A1 7-(NAPHTHALENE-L-YL)PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海和誉生物医药科技有限公司 2023-06-08 WO disclosed
CN-110117285-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2023-02-03 CN disclosed
US-9963428-B1 Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2018-05-08 US disclosed
EP-1892789-B1 LITHIUM SECONDARY BATTERY MITSUBISHI CHEM CORP (JP) 2018-02-28 EP disclosed
US-9598354-B2 Fumarate compounds, pharmaceutical compositions thereof, and methods of use Nguyen, Mark Quang (US) 2017-03-21 US disclosed
US-20160318848-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2016-11-03 US disclosed
US-8946144-B2 Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections THE MEDICINES COMPANY (US) 2015-02-03 US disclosed
EP-0090344-A1 1,3-Dioxolen-2-one derivatives and process for production thereof KANEBO, LTD. (JP) 1983-10-05 EP disclosed
US-4389408-A ANTIBIOTICS CONTAINING A 1,3-DIOXOLENE OR DERIVATIVE RING KANEBO LTD. (JP) 1983-06-21 US disclosed
EP-0078413-A1 Process for producing brominated 1,3-dioxolen-2-ones KANEBO, LTD. (JP) 1983-05-11 EP disclosed
EP-0069962-A1 Novel ester of 1,1-dioxopenicillanic acid, process for production thereof, and use thereof as beta-lactamase inhibitor KANEBO, LTD. (JP) 1983-01-19 EP disclosed
EP-0061206-A1 6-Aminopenicillanic acid esters and their use for producing new ampicillin esters KANEBO, LTD. (JP) 1982-09-29 EP disclosed
US-4342693-A USED FOR INTRODUCING PROTECTIVE GROUPS ON PHARMECUTICALS AND OTHERS KANEBO LTD. (JP) 1982-08-03 US disclosed
EP-0039477-A1 Use of 1,3-Dioxolen-2-one derivatives KANEBO, LTD. (JP) 1981-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318848-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, FPGS, APC ABCG2 618/4885BRD4 3029/4885BRD2 2706/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 ABCG2 1108/4885BRD4 243/4885BRD2 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.